LMAT vs SNY: fair value comparison
LeMaitre Vascular, Inc. and Sanofi · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LMAT currently sits closer to the top of our discount ranking. SNY carries the stronger quality grade.
| LMAT | SNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $103.61 | $42.95 |
| 12-month range | $79.78–$111.76 | $41.63–$47.40 |
| Sector rank | #37 of 113 Healthcare | #41 of 113 Healthcare |
| Quality grade | C+ | B |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: LMAT fair value analysis · SNY fair value analysis